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A pproximately 6000 cases of acute lymphoblastic leukemia (ALL) are diagnosed in the United States annually; half the cases occur in chil dren and teenagers. In the United States, ALL is the most common cancer among children and the most frequent cause of death from cancer before 20 years of age.
1,2 Presenting symptoms of ALL include bruising or bleeding due to thrombo cytopenia, pallor and fatigue from anemia, and infection caused by neutropenia. Leukemic infiltration of the liver, spleen, lymph nodes, and mediastinum is com mon at diagnosis. Extramedullary leukemia in the central nervous system (CNS) or testicles may require specific modifications in therapy.
Since the first description in 1948 of temporary remission of leukemia induced by chemotherapy, 3 pediatric ALL has provided a model for improvement of survival among patients with cancer by progressive improvements in the efficacy of multi agent chemotherapy regimens and by stratification of treatment intensity according to the clinical features of the patient, the biologic features of the leukemia cells, and the early response to treatment, all of which are predictive of the risk of re lapse. Collectively, these advances have increased the survival rate from less than 10% in the 1960s to 90% today (Fig. 1) . New discoveries are revealing the promise and challenges of precisionmedicine strategies that integrate leukemia genomics into contemporary therapy.
Epidemiol ogy a nd R isk Fac t or s
In the United States, the incidence of ALL is about 30 cases per million persons younger than 20 years of age, with the peak incidence occurring at 3 to 5 years of age. 4 The incidence varies significantly according to race and ethnic group: 14.8 cases per million blacks, 35.6 cases per million whites, and 40.9 cases per million Hispan ics. 5 Childhood ALL develops more frequently in boys than in girls (male:female ratio, 55% to 45%).
Several genetic factors (most prominently Down's syndrome 6 ) are associated with an increased risk of ALL, but most patients have no recognized inherited factors. Genomewide association studies have identified polymorphic variants in several genes (including ARID5B, CEBPE, GATA3, and IKZF1) that are associated with an increased risk of ALL or specific ALL subtypes. 79 Rare germline mutations in PAX5 and ETV6 are linked to familial ALL. 10, 11 Few environmental risk factors are associated with ALL in children. Increased rates of the disease have been linked to exposure to radiation and certain chemicals, but these associations explain only a very small minority of cases.
Gene tic Ba sis of A LL
ALL comprises multiple entities with distinct constellations of somatic genetic alterations (Fig. 2) . 12 These genetic alterations include aneuploidy (changes in chro
T h e ne w e ngl a nd jou r na l o f m e dicine mosome number), chromosomal rearrangements that deregulate gene expression or result in ex pression of chimeric fusion proteins, deletions and gains of DNA, and DNA sequence mutations. 13 On average, childhood ALL genomes contain only 10 to 20 nonsilent coding mutations at the time of diagnosis and about twice as many at the time of relapse.
14 Many mutations perturb key cellular processes, including the transcriptional regulation of lymphoid development and differentiation; cellcycle regulation; the TP53-retinoblastoma protein tumorsuppressor pathway; growth factor receptor, Ras, phosphatidylinositol 3kinase, and JAK-STAT signaling; nucleoside metabolism; and epigenetic modification. Perturbation of the latter two processes is common at relapse. 14, 15 ALL may be of Bcell precursor or Tcell lin eage. In 25 to 30% of children with Bcell ALL, leukemic cells have high hyperdiploidy (>50 chromosomes) due to nonrandom chromosome gains. This subtype is associated with an excel lent prognosis. Hypodiploidy (<44 chromosomes) occurs in 2 to 3% of children with Bcell ALL and is a strong negative prognostic factor. 16 Low hypodiploidy (30 to 39 chromosomes), which is associated with the presence of TP53 mutations that are frequently inherited, is a manifestation of the Li-Fraumeni syndrome.
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Chromosomal translocations and intrachro mosomal rearrangements are early, possibly initi ating events in leukemogenesis. Several can be detected in neonatal blood samples years before there are clinical manifestations of leukemia.
18
These translocations and rearrangements are usu ally present in all leukemic cells, are retained at relapse, 14, 19 and with additional genetic alterations, induce leukemia in experimental model systems.
There are two functional classes of transloca tions. The first class relocates oncogenes into regulatory regions of actively transcribed genes, causing dysregulated expression of an intact pro tein. Examples include translocations that bring C-MYC under control of the immunoglobulin heavy chain (IGH) or lightchain (IGK and IGL) gene en hancers in Burkitt's lymphoma and leukemia, rearrangement of the cytokine receptor-like fac tor 2 (CRLF2) and erythropoietin receptor (EPOR) genes to IGH and IGK in Bcell ALL, 20, 21 and jux taposition of the transcription factors TLX1 and TLX3 to Tcell receptor (TCR) loci in Tcell ALL.
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The second major class of translocations jux taposes two genes to encode a chimeric protein that has distinct functions from the proteins from which it is derived. An important example is the ETV6-RUNX1 fusion, which fuses two hema topoietic transcription factors; it is observed in one quarter of children with ALL. Other impor tant examples include TCF3-PBX1, the t(9;22) In several subtypes of ALL, there is no single defining chromosomal alteration, but these sub types are defined by other pathological or ge nomic features. For example, early Tcell precur sor ALL is an aggressive stemcell and progenitor leukemia that has a distinct immunophenotype and genetic alterations targeting transcription factors, signaling pathways, and epigenetic reg ulation. 28, 29 Patients with Phlike ALL have a leukemiccell geneexpression profile that is similar to that in patients with Phpositive ALL, As shown in Panel A, either common inherited variants or, rarely, deleterious germline mutations confer a predisposition to ALL. Initiating lesions, commonly translocations, are acquired in a lymphoid progenitor. Secondary sequence mutations and structural genetic alterations contribute to an arrest in lymphoid development and perturbation of multiple cellular pathways, resulting in clinically manifest leukemia. PI3K denotes phosphatidylinositol 3-kinase. As shown in Panel B, ALL is commonly genetically polyclonal at diagnosis. Initial therapy suppresses or eliminates more proliferative predominant clones, leaving subclones that harbor or acquire mutations that confer resistance to specific chemotherapeutic agents. Less commonly, relapse clones share no genetic alterations with diagnosis clones and probably are a second leukemia in persons with a genetic predisposition. 
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T h e ne w e ngl a nd jou r na l o f m e dicine but they do not have BCRABL1 and harbor a diverse range of genetic alterations that activate tyrosine kinase signaling. 30 The most common of these alterations are fusions that involve "ABLclass" kinases (ABL1, ABL2, CSF1R, and PDGFRB), which can be targeted with ABL1 in hibitors such as imatinib and dasatinib, and fusions, mutations, or deletions that activate JAK-STAT signaling (including rearrangements of JAK2, CRLF2, EPOR, and mutations of JAK1, JAK2, and JAK3 and the interleukin7 receptor).
With the exception of MLL-rearranged leuke mia in infants, each of these subtypes typically has multiple additional genetic alterations. These alterations commonly target genes encoding pro teins involved in cell signaling, tumorsuppressor functions, and lymphoid differentiation. The two most common target genes governing Blymphoid development are PAX5 (mutated in 35% of cases of ALL in children) and IKZF1 (mutated in 15%).
25,31

Prognos tic Fac t or s
Factors that are predictive of an increased or a de creased chance of cure are considered when deci sions are made about the intensity of chemothera py and the selection of patients in first remission for allogeneic hematopoieticcell transplantation (Table 1) . Major prognostic factors include the clinical features that are present at diagnosis, bio logic and genetic features of leukemia cells, and early response to treatment.
Clinical Features
The patient's age and initial whitecell count are predictive of outcome, with older age or a higher whitecell count portending a worse prognosis. A consensus conference defined "standard risk" (age 1 to 9.99 years and initial whitecell count of <50,000 per cubic millimeter) and "high risk" (age ≥10 years, initial whitecell count ≥50,000 per cubic millimeter, or both) ALL subgroups compris ing, respectively, about two thirds and one third of children with Bcell lineage ALL. 32 Infants young er than 1 year are a special subgroup of patients with worse outcomes.
Age and initial whitecell count have limited prognostic importance in Tcell ALL. Several sub types of ALL occur more frequently in certain races and ethnic groups, including TCF3-PBX1 ALL in blacks 33 and CRLF2-rearranged ALL in Hispan ics. 34 Patients with Tcell ALL are often male, black, older and less likely to be Hispanic than patients with Bcell ALL, have higher initial whitecell counts than patients with Bcell ALL, and have mediastinal lymph node and CNS involvement (Ta ble 2). Historically, survival among children with Tcell ALL was inferior to that among children with Bcell ALL. With the use of more intensive therapy, this difference has narrowed substan tially.
37 Some of the preponderance of Tcell ALL among boys and young men may be due to spe cific mutations that target Xchromosome genes.
38,39
Biologic and Genetic Features
Several genetic alterations are associated with the outcome in children with ALL. Alterations of IKZF1, which encodes the lym phoid transcription factor Ikaros, are common in Phpositive and Phlike ALL. These alterations are also associated with a poor outcome.
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Early Response to Treatment
The time required to eliminate the bulk leuke miccell population to undetectable levels is the single most powerful prognostic factor in ALL in children. Acute Lymphoblastic Leukemia in Children The risk of treatment failure and death is 3 to 5 times as high among children with levels of minimal residual disease that are 0.01% or higher at the end of induction therapy and at later time points than among those with levels that are lower than 0.01%. 45, 46, 49, 50 Intensification of thera py for patients with higher levels of minimal re sidual disease improves their outcome.
48,51 Emerg ing nextgenerationsequencing techniques for detection of minimal residual disease may be useful by providing sensitive detection of leuke mia cells below the level detected reliably by other techniques.
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Tr e atment
Improvements in Survival over Time
Almost 50 years ago, combination chemotherapy induced remission (disappearance of clinical evi dence of leukemia and restoration of normal hematopoiesis) in 80 to 90% of children with ALL. However, the disease relapsed in almost all these children, usually in the CNS, with survival rates of 10 to 20%. 53 Survival increased consider ably with the addition of craniospinal or cranial irradiation and intrathecal chemotherapy. 54 A major milestone in therapy for children with ALL was the development of an intensive eightdrug, 8week induction and consolidation regimen as introduced by Riehm et al. 55 This regi men, which is now called protocol I, became the basis for the Berlin-Frankfurt-Münster regimen, which is the core of most contemporary therapies for ALL.
Since this regimen was introduced, large co operative research groups and individual institu tions have enrolled 75 to 95% of children who have a diagnosis of ALL in North America and Western Europe into clinical trials. These trials have led to remarkable improvements in survival, with 5year eventfree survival rates of up to 85% and overall survival rates of up to 90%, according to the most recently reported data (Table 3) .
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Contemporary Therapy
The basic components of various therapies for children with ALL are similar and include sev eral discrete phases. Induction therapy lasts 4 to 6 weeks and includes a glucocorticoid (prednisone or dexamethasone), vincristine, an asparaginase preparation, optional use of an anthracycline, and intrathecal chemotherapy. Almost all patients at tain remission, but this is not a cure, since relapse will occur universally without additional therapy.
After remission, treatment includes 6 to 8 months of intensive combination chemotherapy that is designed to consolidate remission and prevent development of overt CNS leukemia. Treatment in an 8week delayedintensification (protocol II) phase, based on the 8week BerlinFrankfurt-Münster protocol I, is then administered. Repeated courses of methotrexate, administered either through short intravenous infusion or at high doses over 24 hours followed by administration of folinic acid to "rescue" normal tissues from toxic effects, are a critical component of contempo rary ALL regimens.
Patients then receive lowintensity "anti metabolite"based maintenance therapy for 18 to 30 months. This therapy consists of daily oral mercaptopurine or thioguanine and weekly oral methotrexate. Some regimens also include peri odic 5to7day "pulses" of glucocorticoids and vincristine. The exact reasons why maintenance therapy is required and the most effective composi tion and duration of chemotherapy are unknown. Because maintenance therapy is prolonged and requires daily oral drug administration, adherence can be problematic; 20% of patients are less than 90% adherent, and decreased adherence is associ ated with a risk of relapse that is 4 times as high as the risk among patients whose rate of adher ence is 90% or more. 62 Host polymorphisms may influence both the efficacy and toxicity of mer captopurine, which is the backbone of mainte nance therapy.
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CNS-Directed Therapy
Cranial irradiation dramatically improved cure rates among patients with ALL in the 1960s and 1970s, but it was associated with an increased risk of secondary CNS tumors, delayed growth, endocrinopathies, and neurocognitive effects. 64 Consequently, CNS irradiation has been limited to progressively smaller patient subgroups over time.
Several research groups have eliminated CNS irradiation for most or all children with newly diagnosed ALL, and their results are quite simi lar to those obtained by groups that continue to include irradiation in therapy for children with ALL.
56, 59 The current role of CNS irradiation is controversial, but all groups now treat at least 80% of children who have newly diagnosed ALL without the use of cranial irradiation.
Treatment of Relapsed ALL, Including Hematopoietic-Cell Transplantation
Relapse occurs in 15 to 20% of children with ALL, and cure rates are much lower after relapse. 65 Prog nostic factors at relapse include the time to re lapse (a shorter time is associated with a worse prognosis), immunophenotype (Tcell immuno phenotype is associated with a worse prognosis), and the site of relapse (bone marrow disease is associated with a worse prognosis than extra medullary disease). 66 Leukemia cells obtained from patients with early relapse frequently harbor mu tations that decrease sensitivity to common che motherapy drugs. 67, 68 If relapse occurs after the completion of primary treatment, most children will enter a second remission, and the chance for cure is about 50%. If relapse occurs during ther apy, the chance of attaining a second remission is only 50 to 70%, and only 20 to 30% of patients are cured.
Allogeneic hematopoieticcell transplantation is used much more commonly after relapse (in ≥50% of patients) than during primary therapy (in 5 to 10% of patients). Assessment of the mini mal residual disease response may be helpful in determining which patients should undergo trans plantation during a second remission and which patients should not. 69 ALL is frequently a polyclonal disease, and mutations in subclones may be selected by chemo therapy and promote resistance. These include CREBBP mutations that are linked to resistance to glucocorticoids 67 and NT5C2 and PRPS1 mutations that are associated with resistance to thiopu rines. 68, 70, 71 In future studies, it will be important to identify emerging mutations that are associ ated with resistance and explore the potential for modifying therapy to circumvent relapse.
Targeted Therapy and Precision Medicine
The dramatic improvements in survival among children with ALL over the past 50 years are due almost exclusively to identification of the most effective doses and schedules of chemotherapeu tic agents that have been widely available for de cades rather than to the development of new therapies. Recent discoveries regarding the genetic basis of ALL and the development of therapies that target molecular lesions that drive survival of ALL cells have paved the way for the expanding use of precisionmedicine approaches to cancer. 72 One notable example is the use of tyrosine kinase inhibitors in patients with chronic myeloid leu kemia, a cancer that is driven by the BCRABL1 fusion oncoprotein. 73 Treatment with tyrosine ki nase inhibitors (imatinib and related agents) has converted chronic myeloid leukemia from a dis ease requiring intensive therapy that often included hematopoietic stemcell transplantation to a chronic disease that can in most cases be managed success fully for decades with oral tyrosine kinase in hibitors, with the potential for discontinuation of treatment in some patients. 74 The BCRABL1 fusion protein also occurs in 25% of adults and in 3 to 5% of children with ALL (Phpositive ALL), and in ALL, as compared with chronic myeloid leukemia, it is associated with secondary genetic alterations, particularly alterations of IKZF1. 75 Before the use of tyrosine kinase inhibitors, less than half the children with Phpositive ALL survived. 41 Combining ima tinib with cytotoxic chemotherapy has proved to be highly effective in children with Phpositive ALL and has minimized the need for hematopoi eticcell transplantation in the first remission. sis, and it is a logical candidate for individually tailored tyrosine kinase inhibitor therapy. 30,43,79 A diverse range of genetic alterations activate kinase signaling in Phlike ALL; these include a high frequency of rearrangements that converge on a limited number of signaling pathways, including ABLclass and JAK-STAT signaling. Extensive pre clinical studies show that the activation of sig naling pathways induced by these alterations is sensitive to tyrosine kinase inhibitors; this sug gests that precisionmedicine approaches should be successful in this ALL subgroup. These findings are supported by anecdotal reports of dramatic responses of chemotherapyrefractory Phlike ALL to tyrosine kinase inhibitor therapy. 30, 80 This is particularly important in older children and adults, in whom Phlike ALL is more common. 30 An important challenge in the design of future clinical trials will be to ensure adequate enroll ment of patients harboring each class of genetic alteration. To meet this challenge, international clinical trials that involve multiple cooperative groups will have to be developed, as has been done successfully in studies of Phpositive ALL.
Immunotherapy
CD19 is a cellsurface antigen that is present at high density on most Bcell ALL cells. Several groups have developed strategies to transduce au tologous Tcells with an antiCD19 antibody frag ment coupled to intracellular signaling domains of the Tcell receptor, thereby redirecting cytotoxic T lymphocytes to recognize and kill Bcell ALL cells. These chimeric antigen receptor-modified T cells provide a major new treatment option.
In one study, 30 children with heavily pre treated ALL that had relapsed multiple times were treated with chimeric antigen receptor-modified T cells; 90% of the children attained remission, with sustained remission in about two thirds. Approximately three quarters of the children were alive 6 months after the infusion. 81 Remis sions were durable with 1 to 3 years of followup. Many patients had a severe cytokinerelease syndrome after activation of the cytotoxic T cells in vivo. This syndrome was accompanied by high levels of serum interleukin6 that could be treated successfully with the anti-interleukin6 monoclonal antibody tocilizumab. Studies of the durability of chimeric antigen receptor Tcell therapy (ClinicalTrials.gov number, NCT02445222) and its role in patients with ALL who have less advanced disease (NCT02435849) are ongoing.
A different strategy to harness the Tcell im mune response against ALL cells is provided by blinatumomab, a genetically modified antibody that contains fragments that recognize both CD19 and CD3 (which is present on all T cells) and there fore brings T cells into direct contact with Bcell ALL cells, allowing the cytotoxic T cells to kill them. 82 Blinatumomab is now being tested in children with a first relapse of Bcell ALL (NCT02101853).
Short-Term and Long-Term Toxic Effects of Treatment
About 1 to 2% of children with ALL die before attaining remission, and an additional 1 to 2% die from toxic effects during remission. 83 Patients with Down's syndrome, infants, older teenagers, and those receiving more intensive therapy have an increased risk of death from toxic effects, mostly due to infection. Risks can be mitigated by modifications to therapy and supportive care. As cure rates for childhood ALL improve, treat mentrelated death accounts for a higher percent age of all deaths.
One of the most vexing problems associated with contemporary therapy for ALL is osteone crosis, which occurs in 5 to 10% of patients. 84 The risk is much higher among teenagers (15 to 20%) than among young children, and girls are affected more commonly than boys. Osteonecro sis most commonly affects major joints, particu larly the hips, knees, shoulders, and ankles, and often requires surgical management, including joint replacement. Modifications to glucocorti coid administration schedules can decrease the risk of osteonecrosis. 85 Additional treatmentrelated effects include the metabolic syndrome and obesity, cardiovas cular impairment, and CNS and peripheral nervous system toxic effects. Each is caused by highly effec tive antileukemic agents, and a person's risk of toxic effects is influenced by host genetic factors that influence drug metabolism and activity. Thus, an important goal is the tailoring of drug exposure according to the predicted risk of both relapse and specific toxic effects.
A child who is cured of ALL is expected to have 60 to 80 years of remaining life. Critical questions are whether that expected life span is shortened by the leukemia, its treatment, or both, whether chronic health conditions that affect daily life develop at a higher frequency or increased se verity in survivors than in persons who were never treated for childhood ALL, and whether there are lasting emotional or neurocognitive effects that limit full realization of a survivor's poten tial. Unfortunately, many ALL survivors do have chronic toxic effects, 86 and the neurocognitive effects appear to increase as they approach mid dle age. 64 Continued longterm followup of per sons who had ALL in childhood is essential to define the risks and to develop strategies to de crease risks, ameliorate toxic effects, or both.
Implic ations of the Success of Tr e atment
Survival rates among teenagers with ALL are in ferior to those among young children, and sur vival is even worse among young adults. 87, 88 The reasons for these differences are multifactorial and include treatment factors, a higher preva lence of unfavorable genetic subtypes among the older patients, the reduced ability of teenagers and young adults to receive intensive therapy with out untoward side effects, and social factors such as insurance coverage and lack of parental super vision of therapy. Institutions and cooperative groups treating young adults with ALL have suc cessfully adopted treatment modeled on pediatric regimens. This strategy is feasible for patients up to about 50 years of age, with early results sug gesting major improvements in survival. 89 Since the population of children is higher in lowincome and middleincome countries than in highincome countries, the total number of chil dren with a diagnosis of ALL is also higher in these countries; these children have inferior sur vival as compared with children treated in high income countries. 90 Because ALL can be diagnosed with simple techniques and treated successfully with relatively inexpensive chemotherapeutic agents, it is feasible to rapidly improve the outcome in children with ALL in lowincome and middle income countries. Partnerships and "twinning" relationships between centers in highincome cen ters in North America and Western Europe and pediatric cancer centers in Asia, Central and South America, and Eastern Europe have substantially improved survival among children with ALL.
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Conclusions
In the past few years, we have witnessed tremen dous advances in our understanding of the biol ogy of ALL and the remarkable efficacy of targeted chemical and biologic therapeutic approaches in otherwise refractory disease. It is anticipated that in the next several years, the genomic landscape of ALL will be completely described, the biologic causes for treatment failure fully elucidated, and the roles of a range of new chemical and bio logic agents defined. As the cure rate for child hood ALL approaches 100%, major challenges will be to identify persons who require less inten sive therapy to achieve cure and to refine com plex, toxic regimens to incorporate simpler, safer approaches that will result in a high quality of life coupled with longterm survival. 
